Clinical efficacy of beraprost sodium in treating chronic kidney disease: A six-month prospective study

Objective: To investigate the clinical efficacy of beraprost sodium (BPS) in the treatment of chronic kidney disease (CKD). Methods: In this single-centre, prospective, controlled, single-blind study, 252 patients diagnosed with CKD and treated at the Affiliated Hospital of Xuzhou Medical University were enrolled from September 2018 to June 2021. All participants were randomised into three groups: the control, BPS 40 mu g, and BPS 20 mu g groups. Both treatment groups were administered conventional therapy for 6 months. Renal function in the three groups was measured and compared 3 and 6 months post-treatment. Results: 1. Renal function in the BPS 20 mu g and BPS 40 mu g groups was better than that in the control group after 3 and 6 months of treatment. 2. After 3 months of treatment, the levels of serum creatinine (P = 0.043), cystatin C (P = 0.039), and 24 h urinary total protein (P = 0.041) in the BPS 40 mu g group were significantly lower than those in the BPS 20 mu g group, the eGFR (P = 0.046) level was higher than that in the BPS 20 mu g group, and the index improvement rate was better than that in the BPS 20 mu g group (P < 0.05). 3. After 6 months of treatment, the improvement in renal function in the BPS 20 mu g group was close to that in the BPS 40 mu g group (P > 0.05). Conclusion: BPS improved renal function, reduced urinary protein levels, and delayed CKD progression. The clinical efficacy of BPS in the 40 mu g group was faster than that in the BPS 20 mu g group. The long-term use of BPS is effective in patients with CKD.